Company / SG&A Expense
Silo Pharma, Inc. SG&A Expense History
FY2019-FY2023 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest SG&A Expense
$227.3K
FY2023
5-year range
$76.1K / $227.3K
FY2019-FY2023
Trend
+161.2%
vs FY2022
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Increased from $76,076 to $227,259 over the past 4 years.
Based on SEC 10-K filings.
$227,259 in FY2023.
Increased from $76,076 to $227,259 over the past 4 years.
SG&A Expense over time
Growth rates
- 3-Year CAGR
- +37.7%
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- 3-year CAGR of +37.7%, indicating consistent growth.
- In FY2023, sg&a expense increased 161.2% year-over-year.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score 0.67 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | SG&A ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | - | - |
| FY2024 | - | - |
| FY2023 | $227.3K | +161.2% |
| FY2020 | $87.0K | +14.4% |
| FY2019 | $76.1K | - |
As of FY2023 · SEC 10-K · Updated Jun 28, 2026